Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the 2013 Credit Suisse Healthcare Conference

CHICAGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Credit Suisse Healthcare Conference...
October 30, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce Third Quarter 2013 Financial Results on November 6, 2013

CHICAGO, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, November 6th at 8:30 a.m. Eastern Time to discuss third quarter...
October 02, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013(TM)

SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced a comprehensive review of the efficacy, safety and microbiology data of the company's lead...
September 26, 2013 14:48 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

CHICAGO, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX), an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to...
September 25, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Dalbavancin Study Results to be Presented at IDWeek 2013

CHICAGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from the company's lead product candidate, dalbavancin, will be presented in five posters...
September 10, 2013 15:12 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC

DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER ("Dalbavancin for Infections of the Skin...
September 03, 2013 15:03 ET | Source: Durata Therapeutics, Inc.

Dalbavancin Study Results to be Presented in Three Posters at the 53rd Annual ICAAC Meeting

CHICAGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two Phase 3 clinical trials of the company's lead product candidate, dalbavancin, will...
August 07, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics, Inc. Reports Second Quarter 2013 Financial Results

CHICAGO, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2013. Q2 2013 Highlights and Recent...
August 06, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the 2013 Wedbush Securities Life Sciences Management Access Conference

CHICAGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Wedbush Securities Life Sciences...
July 31, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce Second Quarter 2013 Financial Results on August 7, 2013

CHICAGO, July 31, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, August 7th at 8:30 a.m. Eastern Time to discuss second quarter...